disopyramide

Absorption: Well absorbed from the GI tract.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Metabolized by the liver; 10% excreted unchanged in the feces; 50% excreted unchanged by the kidneys.

Half-Life: 8–18 hr (↑ in hepatic or renal impairment).

Time/Action Profile ⬆ ⬇

(antiarrhythmic effects)

ROUTE	ONSET	PEAK	DURATION
PO	0.5–3.5 hr	2.5 hr	1.5–8.5 hr
PO-CR	0.5–3.5 hr	4.9 hr	12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Cardiogenic shock;
2nd- or 3rd-degree heart block;
Sick sinus syndrome (without a pacemaker);
Structural heart disease (coronary artery disease, HF, or valvular disease) (↑ risk of mortality)
;
Lactation: Lactation.

Use Cautiously in:

Renal impairment (dose ↓ recommended if CCr ≤40 mL/min);
Hepatic impairment;
Prostatic enlargement;
Myasthenia gravis;
Glaucoma;
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Geri: May induce HF in older adults.

Adv. Reactions/Side Effects ⬆ ⬇

CV: HF, arrhythmias, dyspnea, edema, heart block, hypotension

EENT: dry eyes, blurred vision, dry throat

Endo: hypoglycemia

GI: constipation, dry mouth, abdominal pain, flatulence, nausea

GU: urinary hesitancy, urinary retention

Neuro: fatigue, dizziness, headache

Misc: impaired temperature regulation

Interactions ⬆ ⬇

Drug-drug:

May potentiate anticoagulant effect of warfarin.
Rifampin, phenobarbital, and phenytoin may ↓ levels and effectiveness.
Cimetidine or erythromycin may ↑ levels and risk of toxicity.
May have additive toxic cardiac effects when used with other antiarrhythmics (prolonged conduction and ↓ cardiac output), especially verapamil; avoid using disopyramide for 48 hr before or 24 hr after.
Anticholinergic side effects may be additive with other drugs having anticholinergic properties, including antihistamines and TCAs.
↑risk of arrhythmias with pimozide.

Drug-Natural Products:

↑anticholinergic effects with angel's trumpet, jimson weed, and scopolia.

Route/Dosage ⬆ ⬇

PO (Adults >50 kg): 150 mg every 6 hr (as immediate-release capsules) or 300 mg every 12 hr (as CR dosage form); not to exceed 800 mg/day.
PO (Adults <50 kg or Patients with Poor Left Ventricular Function): 100 mg every 6–8 hr (as immediate-release capsules) or 200 mg every 12 hr (as CR dosage form).
PO (Children 12–18 yr): 6–15 mg/kg daily, in divided doses every 6 hr.
PO (Children 4–12 yr): 10–15 mg/kg daily in divided doses every 6 hr.
PO (Children 1–4 yr): 10–20 mg/kg daily in divided doses every 6 hr.
PO (Children <1 yr): 10–30 mg/kg daily in divided doses every 6 hr.

Renal Impairment

PO (Adults ): CCr >40 mL/min or patients with hepatic impairment: 100 mg every 6 hr; CCr 30–40 mL/min: 100 mg every 8 hr; CCr 15–30 mL/min: 100 mg every 12 hr; CCr <15 mL/min: 100 mg every 24 hr as immediate-release dosage form.

Availability ⬆ ⬇

(Generic available)

Capsules: 100 mg; 150 mg
Extended-release capsules: 100 mg; 150 mg

Assessment ⬆ ⬇

Monitor BP, HR, and ECG before and routinely during therapy. Check HR before administering medication; hold and notify health care provider if <60 or >120 bpm or if changes in rhythm.
Monitor intake and output and daily weight; assess for edema and urinary retention daily.
Assess patient for signs of HF (peripheral edema, rales/crackles, dyspnea, weight gain, jugular venous distention). Notify health care provider if these occur.

Lab Test Considerations:

Renal and hepatic function and serum potassium levels should be evaluated periodically throughout therapy.
- May ↑ serum BUN, cholesterol, and triglyceride levels.
- May ↓ blood glucose concentrations.

Implementation ⬆ ⬇

Do not confuse disopyramide with desipramine.
Because of lack of evidence of improved survival in patients without life-threatening arrhythmias, use of disopyramide should be reserved for patients with life-threatening ventricular arrhythmias.
When changing from quinidine sulfate to disopyramide, regular maintenance dose of disopyramide may be given 6–12 hr after last dose of quinidine sulfate.
- Extended-release form (CR formulations) is indicated for maintenance therapy only. When changing from regular form to extended-release forms, give the first dose of extended-release form 6 hr after the last regular dose.
PO: Administer medication on an empty stomach, 1 hr before or 2 hr after meals, around the clock, not 4 times/day to maintain therapeutic blood levels.
- DNC: CR form must be swallowed whole; do not break open, crush, or chew.
- Pharmacist may prepare a suspension with 100-mg capsules and cherry syrup.

Patient/Family Teaching ⬆ ⬇

Advise patient to take medication around the clock, as directed. Do not discontinue medication without consulting health care provider. If a dose is missed, take as soon as remembered unless within 4 hr of next dose. Do not double doses.
Medication may cause dizziness. Caution patients to avoid driving or other activities requiring alertness until response to medication is known.
Instruct patient to change positions slowly to minimize orthostatic hypotension.
Advise patient that frequent mouth rinses, good oral hygiene, and sugarless gum or candy may help relieve dry mouth.
Caution patient to avoid extremes of temperature, because this medication may cause impairment of body temperature regulation. Patient should use sunscreen and protective clothing to prevent photosensitivity reactions.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care provider before taking other Rx, OTC, herbal products, or alcohol.
If constipation becomes a problem, advise patient that ↑ bulk and fluids in the diet and exercising may minimize constipation.
Instruct patient to notify health care provider if dry mouth, difficult urination, constipation, or blurred vision persists.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care provider promptly if pregnancy is planned or suspected and to avoid breastfeeding during therapy.

Evaluation/Desired Outcomes ⬆ ⬇

Suppression of ventricular arrhythmias.

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Code ⬆

NDC Code

0025- Pfizer Laboratories Div Pfizer Inc
- 0025-2732- Norpace CR
  - 0025-2732-31- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31)

0025- Pfizer Laboratories Div Pfizer Inc
- 0025-2742- Norpace CR
  - 0025-2742-31- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2742-31)

0025- Pfizer Laboratories Div Pfizer Inc
- 0025-2752- Norpace
  - 0025-2752-31- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2752-31)

0025- Pfizer Laboratories Div Pfizer Inc
- 0025-2762- Norpace
  - 0025-2762-31- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2762-31)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-3127- Disopyramide Phosphate
  - 0093-3127-01- 100 CAPSULE in 1 BOTTLE (0093-3127-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-3129- Disopyramide Phosphate
  - 0093-3129-01- 100 CAPSULE in 1 BOTTLE (0093-3129-01)

51014- PCAS FINLAND
- 51014-7863-
  - 51014-7863-0- 45 kg in 1 DRUM (51014-7863-0)

51862- Mayne Pharma Commercial LLC
- 51862-095- DISOPYRAMIDE PHOSPHATE
  - 51862-095-01- 100 CAPSULE in 1 BOTTLE (51862-095-01)

55512- Archimica S.p.A.
- 55512-0004-
  - 55512-0004-0- 50 kg in 1 DRUM (55512-0004-0)

59762- Mylan Pharmaceuticals Inc.
- 59762-0386- Disopyramide Phosphate
  - 59762-0386-1- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0386-1)

59762- Mylan Pharmaceuticals Inc.
- 59762-0400- Disopyramide Phosphate
  - 59762-0400-1- 100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0400-1)

68259- Sumitomo Chemical Company, Limited
- 68259-1304-
  - 68259-1304-1- 50 kg in 1 CONTAINER (68259-1304-1)

75907- Dr. Reddy's Labratories Inc.
- 75907-026- DISOPYRAMIDE PHOSPHATE
  75907-026-01- 100 CAPSULE in 1 BOTTLE (75907-026-01)

75907- Dr. Reddy's Labratories Inc.
- 75907-027- DISOPYRAMIDE PHOSPHATE
  - 75907-027-01- 100 CAPSULE in 1 BOTTLE (75907-027-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇